Aerosol therapy in acute respiratory distress syndrome: from bench to bedside—drug evidence, delivery constraints, and a phenotype-informed translational framework

Acute respiratory distress syndrome (ARDS) is a heterogeneous form of acute lung injury characterized by alveolar-capillary barrier disruption, pulmonary edema, surfactant dysfunction and ventilation-perfusion mismatch. Lung-protective ventilation, appropriate positive end-expiratory pressure (PEEP), prone positioning when indicated, and treatment of the precipitating cause remain central to care. Aerosolized therapies are attractive because they may achieve local respiratory exposure, but the nominal dose loaded into a device is not equivalent to emitted dose, airway-delivered mass, regional deposition or biologically active target exposure. This narrative review examines aerosol therapy across drug biology, aerosol technology, respiratory-support configuration and ARDS phenotype. It summarizes evidence for inhaled pulmonary vasodilators, β2-agonists, nebulized heparin, inhaled corticosteroids, exogenous surfactant, inhaled antibiotics and secretion-directed therapies, while distinguishing gaseous inhaled nitric oxide (iNO) from particle-based aerosol delivery. iNO and inhaled prostacyclins may improve oxygenation in selected patients, but consistent patient-centred benefit has not been established; other aerosol strategies remain indication-specific or investigational. Device output, formulation, particle characteristics, circuit geometry, humidification, artificial airway, ventilator settings, interface leakage and regional aeration can alter exposure. Recent practice data demonstrate frequent aerosol use and suboptimal device positioning in some intensive care settings, but do not establish that positioning differences cause worse outcomes. We propose a phenotype-informed translational pathway linking biological target, patient characteristics, aerosol accessibility, drug-device selection, delivery fidelity, response assessment and stopping criteria. This framework is conceptual and requires prospective validation. Future studies should standardize exposure reporting, measure deposition where feasible, prespecify patient phenotypes and clinically meaningful outcomes, and preserve lung-protective care and safety.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-20
DOI
https://doi.org/10.3389/fmed.2026.1969715
Primary Topic
Respiratory Support and Mechanisms
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Aerosol therapy in acute respiratory distress syndrome: from bench to bedside—drug evidence, delivery constraints, and a phenotype-informed translational framework

Srishankar Bairy, Carishma Sheela, Eldhos Jacob
1 links
Frontiers in Medicine
Respiratory Support and Mechanisms
article

Aerosol therapy in acute respiratory distress syndrome: from bench to bedside—drug evidence, delivery constraints, and a phenotype-informed translational framework

Srishankar Bairy, Carishma Sheela, Eldhos Jacob
article en

Abstract

Acute respiratory distress syndrome (ARDS) is a heterogeneous form of acute lung injury characterized by alveolar-capillary barrier disruption, pulmonary edema, surfactant dysfunction and ventilation-perfusion mismatch. Lung-protective ventilation, appropriate positive end-expiratory pressure (PEEP), prone positioning when indicated, and treatment of the precipitating cause remain central to care. Aerosolized therapies are attractive because they may achieve local respiratory exposure, but the nominal dose loaded into a device is not equivalent to emitted dose, airway-delivered mass, regional deposition or biologically active target exposure. This narrative review examines aerosol therapy across drug biology, aerosol technology, respiratory-support configuration and ARDS phenotype. It summarizes evidence for inhaled pulmonary vasodilators, β2-agonists, nebulized heparin, inhaled corticosteroids, exogenous surfactant, inhaled antibiotics and secretion-directed therapies, while distinguishing gaseous inhaled nitric oxide (iNO) from particle-based aerosol delivery. iNO and inhaled prostacyclins may improve oxygenation in selected patients, but consistent patient-centred benefit has not been established; other aerosol strategies remain indication-specific or investigational. Device output, formulation, particle characteristics, circuit geometry, humidification, artificial airway, ventilator settings, interface leakage and regional aeration can alter exposure. Recent practice data demonstrate frequent aerosol use and suboptimal device positioning in some intensive care settings, but do not establish that positioning differences cause worse outcomes. We propose a phenotype-informed translational pathway linking biological target, patient characteristics, aerosol accessibility, drug-device selection, delivery fidelity, response assessment and stopping criteria. This framework is conceptual and requires prospective validation. Future studies should standardize exposure reporting, measure deposition where feasible, prespecify patient phenotypes and clinically meaningful outcomes, and preserve lung-protective care and safety.

Frontiers in MedicineVol. 13
Father Muller Medical College Hospital (IN)
Good health and well-being
Respiratory Support and Mechanisms
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon